Search Results

You are looking at 1 - 10 of 1,743 items for :

  • "Chemotherapy" x
Clear All
Full access

Gary H. Lyman

Dr. Lyman has disclosed that he receives research grant support from Amgen Inc. References 1 Crawford J Dale DC Kuderer NM . Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of

Full access

David C. Dale, Gordon C. McCarter, Jeffrey Crawford and Gary H. Lyman

results of 20 years of follow-up . N Engl J Med 1995 ; 332 : 901 – 906 . 2 Wood WC Budman DR Korzun AH . Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma . N Engl J Med 1994 ; 330 : 1253

Full access

George M. Rodgers III, Pamela Sue Becker, Morey Blinder, David Cella, Asher Chanan-Khan, Charles Cleeland, Peter F. Coccia, Benjamin Djulbegovic, Jeffrey A. Gilreath, Eric H. Kraut, Ursula A. Matulonis, Michael M. Millenson, Denise Reinke, Joseph Rosenthal, Rowena N. Schwartz, Gerald Soff, Richard S. Stein, Gordana Vlahovic and Alva B. Weir III

guidelines underwent substantial revisions. The purpose of these guidelines is 2-fold: 1) to operationalize the evaluation and treatment of anemia in adult patients with cancer, with an emphasis on those with anemia who are receiving concomitant chemotherapy

Full access

Jerome Kim and Arti Hurria

of Determining Potential Toxicities A major concern when treating geriatric patients with cancer is the risk for chemotherapy-related toxicities. Although trials show that chemotherapy is effective in patients with “good” functional status, the same

Full access

Katya Losk, Ines Vaz-Luis, Kristen Camuso, Rafael Batista, Max Lloyd, Mustafa Tukenmez, Mehra Golshan, Nancy U. Lin and Craig A. Bunnell

Background Over the past 50 years, substantial reductions in early breast cancer mortality have been documented due to a combination of earlier detection and to advances in adjuvant treatment. 1 – 4 In particular, adjuvant chemotherapy has

Full access

Viola Walter, Daniel Boakye, Janick Weberpals, Lina Jansen, Walter E. Haefeli, Uwe M. Martens, Phillip Knebel, Jenny Chang-Claude, Michael Hoffmeister and Hermann Brenner

primarily treated by surgery, followed by adjuvant chemotherapy under certain conditions. Adjuvant treatment of stage II colon cancer is controversial 3 and mostly restricted to high-risk patients. 4 – 7 However, adjuvant chemotherapy has been widely

Full access

Daphna Y. Spiegel, Matthew J. Boyer, Julian C. Hong, Christina D. Williams, Michael J. Kelley, Joseph K. Salama and Manisha Palta

resection and consideration of adjuvant chemotherapy (AC) based on patient and tumor characteristics. The role of AC in colon cancer is supported by the results of NSABP C01, 1 a pooled analysis, 2 and the MOSAIC trial 3 showing improvement in disease

Full access

James M. Hoffman, Donald K. Baker, Scott C. Howard, Joseph H. Laver and Jerry L. Shenep

Various programs are ongoing to promote the implementation of EHRs and CPOE, including federal incentives that will become available in 2011. 4 Specific data on the use of CPOE for chemotherapy are limited, but CPOE for chemotherapy seems to lag behind

Full access

Davinia S.E. Seah, Ines Vaz Luis, Erin Macrae, Jessica Sohl, Georgia Litsas, Eric P. Winer, Nancy U. Lin and Harold J. Burstein

+ breast cancer; and HER2-directed therapies for HER2-amplified breast cancer. 15 , 16 However, despite the heterogeneity of breast cancer, almost all patients with MBC will receive chemotherapy at some point. Compared with patients who have other solid

Full access

Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page and Chun Chao

Background Febrile neutropenia (FN) is a serious adverse effect of myelosuppressive chemotherapy that can affect treatment by contributing to dose delays and reductions. 1 FN often requires hospitalization and incurs a significant healthcare